Viral Clearance Market

Viral removal is estimated at 51.0% in 2026 while recombinant proteins are projected at 34.0% by application and pharmaceutical and biotechnology companies account for 51.0% by end user. Adoption depends on representative scale-down models and sensitive assays that preserve detection limits across orthogonal clearance steps.